Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982575 · ClinicalTrials.gov registry record · Phase 2
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT04982575 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 92 participants.
The verdict
NCT04982575, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective. Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance. A dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected. Participants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how. The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor. At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed). Women who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period
Interventions
- DRUG Placebo (semaglutide)
- DRUG Semaglutide 2.4 mg
- DRUG Cagrilintide 2.4 mg
- DRUG Placebo (cagrilintide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04982575
The ClinicalTrials.gov registry entry for NCT04982575 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (semaglutide) is the first listed.
NCT04982575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04982575 about?
NCT04982575 is a clinical study titled "Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes". This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and ...
What is the current status of trial NCT04982575?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2021-08-02. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT04982575?
The interventions under investigation include: Placebo (semaglutide) (DRUG), Semaglutide 2.4 mg (DRUG), Cagrilintide 2.4 mg (DRUG), Placebo (cagrilintide) (DRUG).
Who is sponsoring clinical trial NCT04982575?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.